产品
编 号：F760698
分子式：C29H32Cl2N4O5
分子量：587.49
分子式：C29H32Cl2N4O5
分子量：587.49
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 851333-14-7
产品详情
生物活性：
EMD527040 is a potent and highly selective αvβ6 antagonist with antifibrotic activities. EMD527040 can be used for carcinoma and liver fibrosis research.
体内研究：
EMD527040 (intraperitoneal?injection; 20-60 mg/kg; week 2 to 6 after BDL) attenuates bile ductular proliferation and peribiliary collagen deposition by 40-50%, induces downregulation of fibrogenic and upregulation of fibrolytic genes, and improves liver architecture and function. EMD527040 significantly reduced liver and spleen weights by 22% and 50%, respectively in Mdr2(Abcb4)-/- mice.Animal Model:Male adult Wistar rats
Dosage:20-60 mg/kg
Administration:Intraperitoneal?injection; 20-60 mg/kg; week 2 to 6 after BDL (bile duct ligation)
Result:Ameliorated fibrosis progression in rodents with biliary fibrosis.
体外研究：
EMD527040 inhibits binding of recombinant αvβ6 to fibronectin at 6 nM as compared to >9.5 μM for αvβ3 and αvβ5 integrins (IC5050).EMD527040 inhibits the attachment of αvβ6 expressing cells (UCLAP3 cells) to fibronectin at IC50 of 1.6 μM, as compared to >50 μM for αvβ3 and αvβ5 integrins.
EMD527040 is a potent and highly selective αvβ6 antagonist with antifibrotic activities. EMD527040 can be used for carcinoma and liver fibrosis research.
体内研究：
EMD527040 (intraperitoneal?injection; 20-60 mg/kg; week 2 to 6 after BDL) attenuates bile ductular proliferation and peribiliary collagen deposition by 40-50%, induces downregulation of fibrogenic and upregulation of fibrolytic genes, and improves liver architecture and function. EMD527040 significantly reduced liver and spleen weights by 22% and 50%, respectively in Mdr2(Abcb4)-/- mice.Animal Model:Male adult Wistar rats
Dosage:20-60 mg/kg
Administration:Intraperitoneal?injection; 20-60 mg/kg; week 2 to 6 after BDL (bile duct ligation)
Result:Ameliorated fibrosis progression in rodents with biliary fibrosis.
体外研究：
EMD527040 inhibits binding of recombinant αvβ6 to fibronectin at 6 nM as compared to >9.5 μM for αvβ3 and αvβ5 integrins (IC5050).EMD527040 inhibits the attachment of αvβ6 expressing cells (UCLAP3 cells) to fibronectin at IC50 of 1.6 μM, as compared to >50 μM for αvβ3 and αvβ5 integrins.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备